news)

NEWS

Media Contacts:

Europe

Robert Sutherland
Mobile: +44  7917 551 666
Email: robert.sutherland@seqirus.com

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Asia Pacific

Melanie Kerin
Mobile: +61 (0) 417 436 329
Email: melanie.kerin@seqirus.com

Seqirus news releases

Seqirus news releases

Seqirus opens new Italian headquarters
19 Jul 2019

Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena.

Anjana Narain to Lead Seqirus Influenza Vaccines Business
17 Jul 2019

CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world’s largest influenza vaccines providers.

Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
15 Jul 2019

This news release is intended for business and trade media only.

First cell-based quadrivalent influenza vaccine approved for use in Europe
14 Jan 2019

This news release is intended for Health Professional media only.

Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
16 Nov 2018 News Release

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

New Data on Cell-Based Seasonal Influenza Vaccines
16 Nov 2018

This news release is intended for Health Professional media only.